专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07481936B2 Method and apparatus for patient fluid management 失效
标题翻译：患者流体管理的方法和装置
公开(公告)号：US07481936B2
公开(公告)日：2009-01-27
申请号：US11078016
申请日：2005-03-11
申请人： Reynolds G. Gorsuch , Harold H. Handley , Harold W. Peters
发明人： Reynolds G. Gorsuch , Harold H. Handley , Harold W. Peters
IPC分类号： B01D61/14 , B01D61/18 , B01D63/02 , B01D63/04 , B01D61/00 , B01D63/00
CPC分类号： A61M1/1678 , A61M1/1682 , A61M1/34 , A61M1/3406 , A61M1/3431 , A61M1/3472 , A61M1/3479 , A61M1/3486 , A61M1/3496 , A61M2205/15 , A61M2205/50 , B01D63/02 , B01D63/024 , B01D2313/10
摘要： Patient fluid management is carried out by separating plasma from whole blood in vivo via an implantable filter device comprising one or more elongated hollow tubes and a plurality of elongated microporous fibers having an interior lumen extending along the length thereof, each fiber having a first and second end secured to the one or more elongated hollow tubes by passing plasma through the fiber wall from the outer wall surface to the inner wall surface and to the interior fiber lumen, directing the separated plasma to an ultrafiltration apparatus having a sieving coefficient cutoff between about 1×104 and about 6×104 daltons, separating plasma water and selected plasma components, from the separated plasma, and directing the treated plasma to the patient.
摘要翻译：患者液体管理是通过经由包括一个或多个细长中空管的可植入过滤器装置和具有沿着其长度延伸的内腔的多个细长微孔纤维在体内分离全血的血浆进行的，每个纤维具有第一和第二通过将等离子体通过纤维壁从外壁表面传递到内壁表面和内部纤维内腔，将分离的等离子体引导到超滤装置，其中筛分系数截止值在约1×10 4 和约6×10 4道尔顿，从分离的血浆中分离血浆水和选定的血浆成分，并将治疗的血浆引导至患者。

2. 发明授权

US6051229A Human-human hybridom for neoplasms CLNH5 and CLNH11 specific antibody compositions 失效
标题翻译：用于肿瘤的人 - 人类杂交瘤CLNH5和CLNH11特异性抗体组合物
公开(公告)号：US6051229A
公开(公告)日：2000-04-18
申请号：US443810
申请日：1995-05-18
申请人： Harold H. Handley , Mark C. Glassy , Hideaki Hagiwara , Yoshihide Hagiwara
发明人： Harold H. Handley , Mark C. Glassy , Hideaki Hagiwara , Yoshihide Hagiwara
IPC分类号： C07K16/18 , A61K20060101 , A61K39/395 , A61K47/48 , A61K51/10 , A61P35/00 , C07K16/30 , C12N5/00 , C12N5/24 , C12N15/00 , C12P21/00 , C12P21/02 , G01N33/50 , G01N33/53 , G01N33/577
CPC分类号： A61K47/48823 , A61K47/48569 , A61K51/1045 , C07K16/30 , A61K2039/505 , C07K2317/21
摘要： CLNH5 and CLNH11 specific hybridomas, human monoclonal antibodies and their uses are provided. The antibodies distinguish a human neoplastic cell from a normal cell of the same tissue type. The monoclonal antibodies find use in therapy and diagnosis, both in vitro and in vivo.
摘要翻译：提供CLNH5和CLNH11特异性杂交瘤，人单克隆抗体及其用途。抗体将人肿瘤细胞与相同组织类型的正常细胞区分开。单克隆抗体在体外和体内均可用于治疗和诊断。

3. 发明申请

US20120037564A1 METHODS AND SYSTEMS FOR REDUCING VIRAL LOAD OF HEPATITIS C VIRUS IN HEMODIALYSIS PATIENTS 审中-公开
标题翻译：用于减少HEMODIALYSIS患者中HEPATITIS C病毒的病毒载体的方法和系统
公开(公告)号：US20120037564A1
公开(公告)日：2012-02-16
申请号：US13049804
申请日：2011-03-16
申请人： Richard H. Tullis , Harold H. Handley , James A. Joyce , Paul R. Duffin
发明人： Richard H. Tullis , Harold H. Handley , James A. Joyce , Paul R. Duffin
IPC分类号： B01D15/38 , B01D61/24
CPC分类号： C12N7/00 , A61M1/3679 , A61M2202/206 , C12N2770/24251
摘要： The present technology relates to methods and systems for the removal of pathogens and fragments thereof in hemodialysis patients. In particular, methods and systems are described where lectins can be used to remove the Hepatitis C virus and fragments thereof in hemodialysis patients, and to provide a sustained reduction in viral load.
摘要翻译：本技术涉及用于在血液透析患者中除去病原体及其片段的方法和系统。特别地，描述了在血液透析患者中可以使用凝集素去除丙型肝炎病毒及其片段的方法和系统，并提供病毒载量的持续降低。

4. 发明授权

US6090924A Human-Human CLNH5-specific antibodies 失效
标题翻译：人类人类CLNH5特异性抗体
公开(公告)号：US6090924A
公开(公告)日：2000-07-18
申请号：US482195
申请日：1995-06-07
申请人： Harold H. Handley , Mark C. Glassy , Hideaki Hagiwara , Yoshihide Hagiwara
发明人： Harold H. Handley , Mark C. Glassy , Hideaki Hagiwara , Yoshihide Hagiwara
IPC分类号： A61K38/00 , A61K47/48 , A61K51/10 , C07K16/30 , C12N5/22 , A61K39/395
CPC分类号： C07K16/30 , A61K51/1045 , A61K2039/505 , A61K38/00 , C07K2317/21 , Y10S435/948 , Y10S436/813 , Y10S530/865
摘要： CLNH5-specific hybridomas, human monoclonal antibodies and their uses are provided. The antibodies distinguish a human neoplastic cell from a normal cell of the same tissue type. The monoclonal antibodies find use in therapy and diagnosis, both in vitro and in vivo.
摘要翻译：提供了CLNH5特异性杂交瘤，人单克隆抗体及其用途。抗体将人肿瘤细胞与相同组织类型的正常细胞区分开。单克隆抗体在体外和体内均可用于治疗和诊断。

5. 发明授权

US6051693A CLNH11-specific antibodies 失效
标题翻译： CLNH11特异性抗体
公开(公告)号：US6051693A
公开(公告)日：2000-04-18
申请号：US482197
申请日：1995-06-07
申请人： Harold H. Handley , Mark C. Glassy , Hideaki Hagiwara , Yoshihide Hagiwara
发明人： Harold H. Handley , Mark C. Glassy , Hideaki Hagiwara , Yoshihide Hagiwara
IPC分类号： C07K16/18 , A61K20060101 , A61K39/395 , A61K47/48 , A61K51/10 , A61P35/00 , C07K16/30 , C12N5/00 , C12N5/24 , C12N15/00 , C12P21/00 , C12P21/02 , G01N33/50 , G01N33/53 , G01N33/577
CPC分类号： A61K47/48823 , A61K47/48569 , A61K51/1045 , C07K16/30 , A61K2039/505 , C07K2317/21
摘要： CLNH11-specific hybridomas, human monoclonal antibodies and their uses are provided. The antibodies distinguish a human neoplastic cell from a normal cell of the same tissue type. The monoclonal antibodies find use in therapy and diagnosis, both in vitro and in vivo.
摘要翻译：提供了CLNH11特异性杂交瘤，人单克隆抗体及其用途。抗体将人肿瘤细胞与相同组织类型的正常细胞区分开。单克隆抗体在体外和体内均可用于治疗和诊断。

6. 发明授权

US5286647A Human-human hybridomas for neoplasms 失效
标题翻译：人 - 人类杂交瘤肿瘤
公开(公告)号：US5286647A
公开(公告)日：1994-02-15
申请号：US113212
申请日：1987-10-23
申请人： Harold H. Handley , Mark C. Glassy , Ideaki Hagiwara , Yoshihide Hagiwara
发明人： Harold H. Handley , Mark C. Glassy , Ideaki Hagiwara , Yoshihide Hagiwara
IPC分类号： A61K38/00 , A61K47/48 , A61K51/10 , C07K16/30 , C12N5/12
CPC分类号： A61K51/1045 , C07K16/30 , A61K2039/505 , A61K38/00 , C07K2317/21 , Y10S424/808 , Y10S436/813 , Y10S530/809 , Y10S530/865
摘要： Novel hybridomas, human monoclonal antibodies and their uses are provided. The antibodies distinguish a human neoplastic cell from a normal cell of the same tissue type. The monoclonal antibodies find use in therapy and diagnosis, both in vitro and in vivo.
摘要翻译：提供了新的杂交瘤，人单克隆抗体及其用途。抗体将人肿瘤细胞与相同组织类型的正常细胞区分开。单克隆抗体在体外和体内均可用于治疗和诊断。

7. 发明授权

US4618577A Human-human hybridoma, CLNH5 失效
标题翻译：人 - 人杂交瘤，CLNH5
公开(公告)号：US4618577A
公开(公告)日：1986-10-21
申请号：US465081
申请日：1983-02-09
申请人： Harold H. Handley , Mark C. Glassy , Yoshihide Hagiwara , Hideaki Hagiwara
发明人： Harold H. Handley , Mark C. Glassy , Yoshihide Hagiwara , Hideaki Hagiwara
IPC分类号： A61K38/00 , A61K47/48 , A61K51/10 , C07K16/30 , C12N5/22 , G01N33/53 , C12N5/00 , C12N15/00 , C12P21/00 , C12R1/91
CPC分类号： C07K16/30 , A61K51/1045 , A61K2039/505 , A61K38/00 , C07K2317/21 , Y10S435/948 , Y10S436/813 , Y10S530/865
摘要： Novel hybridomas, human monoclonal antibodies, and their uses are provided. Specifically CLNH5 is a human-human hybridoma which secretes IgM monoclonal antibodies specific for cervical of carcinomas. The monoclonal antibodies can find use in therapy and diagnosis, both in vitro and in vivo.The hybridoma CLNH5 was deposited at the A.T.C.C. for patent purposes as defined in M.P.E.P. 608.01(p) on Jan. 28, 1983 and given A.T.C.C. Accession No. HB8206.
摘要翻译：提供了新型杂交瘤，人单克隆抗体及其用途。特别地，CLNH5是分泌针对癌症宫颈特异性的IgM单克隆抗体的人 - 人杂交瘤。单克隆抗体可用于体外和体内的治疗和诊断。杂交瘤CLNH5保藏在A.T.C.C. 用于专利目的，如M.P.E.P. 1983年1月28日608.01（p），并提供A.T.C.C. 登录号HB8206。

8. 发明申请

US20110284463A1 DEVICE AND METHOD FOR PURIFYING VIRALLY INFECTED BLOOD 审中-公开
标题翻译：用于净化真菌感染血液的装置和方法
公开(公告)号：US20110284463A1
公开(公告)日：2011-11-24
申请号：US12600236
申请日：2008-05-16
申请人： Richard H. Tullis , Harold H. Handley , James A. Joyce , Paul Duffin
发明人： Richard H. Tullis , Harold H. Handley , James A. Joyce , Paul Duffin
IPC分类号： A61M1/34 , B01D15/00
CPC分类号： A61M1/362 , A61M1/3486 , A61M1/3679 , A61M2202/097 , A61M2202/206 , A61M2205/273 , B01D15/22 , B01D15/3823 , B01D61/027 , B01D69/02 , B01D69/08 , B01D2325/02
摘要： The present invention relates to a method for using lectins that bind to pathogens having surface glycoproteins or fragments thereof which contain glycoproteins, to remove them from infected blood or plasma or other fluids in an extracorporeal setting. Accordingly, the present invention provides a methods and devices for reducing viral load or plaque forming units in blood or plasma from one or more infected individuals. A preferred embodiment of the method comprises passing the blood or plasma through a porous hollow fiber membrane wherein lectin molecules are disposed proximate to the membrane, collecting pass-through blood or plasma and optionally reinfusing the pass-through blood or plasma into the individual. Additionally, the present invention provides a methods and devices for the reduction of plaque forming units, cleared more rapidly and more efficiently than overall viral load.
摘要翻译：本发明涉及一种使用凝集素结合病原体的方法，所述凝集素含有含有糖蛋白的表面糖蛋白或其片段，以将其从感染的血液或血浆或体外其它液体中除去。因此，本发明提供了用于减少来自一个或多个受感染个体的血液或血浆中病毒载量或斑块形成单位的方法和装置。该方法的优选实施方案包括使血液或血浆通过多孔中空纤维膜，其中凝集素分子靠近膜设置，收集直通血液或血浆，并可选择地将直通血液或血浆重新灌注到个体中。此外，本发明提供了减少斑块形成单位的方法和装置，其比全部病毒载量更快速和更有效地清除。

9. 发明申请

US20110009796A1 METHOD AND APPARATUS FOR INCREASING CONTAMINANT CLEARANCE RATES DURING EXTRACORPOREAL FLUID TREATMENT 审中-公开
标题翻译：在超临界流体处理过程中增加污染物清除率的方法和装置
公开(公告)号：US20110009796A1
公开(公告)日：2011-01-13
申请号：US12810295
申请日：2008-12-19
申请人： Richard H. Tullis , Harold H. Handley , Paul Duffin
发明人： Richard H. Tullis , Harold H. Handley , Paul Duffin
IPC分类号： A61M1/34 , B01D63/02 , B01D15/00 , B01D61/00
CPC分类号： A61M1/3486
摘要： An extracorporeal fluid treatment apparatus includes a separator comprising a cartridge surrounding a porous separation membrane. The membrane separates a main flow path of a cellular component of the blood from a plasma flow path. An affinity medium is disposed within the plasma flow path to bind contaminants such as viral pathogens or toxins contained within the plasma. A pump pumps the plasma through the affinity medium at an assisted flow rate preferably between 10% and 40% of the whole blood flow rate. The assisted flow rate is selected to reduce a T90% of the apparatus by at least 50% as compared to a T90% of the apparatus without the plasma pump. A method of treating blood containing contaminants includes supplying infected blood to a separator and pumping the plasma component through an affinity medium at an assisted flow rate to increase contaminant clearance.
摘要翻译：一种体外流体处理设备包括一个分离器，该分离器包括围绕多孔分离膜的盒。膜将血液的细胞成分的主流路与等离子体流路分开。亲和介质设置在等离子体流动路径内以结合血浆中包含的病毒病原体或毒素等污染物。泵以相对于全血流量的10％至40％的辅助流速泵送血浆通过亲和介质。与没有等离子体泵的装置的T90％相比，选择辅助流速以将装置的T90％降低至少50％。一种处理含有污染物的血液的方法包括将受感染的血液供应到分离器并以辅助流速泵送血浆成分通过亲和介质以增加污染物清除率。

10. 发明授权

US06051387A Methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies 失效
标题翻译：用CLNH5和CLNH11特异性抗体测定肿瘤存在的方法
公开(公告)号：US06051387A
公开(公告)日：2000-04-18
申请号：US480014
申请日：1995-06-07
申请人： Harold H. Handley , Mark C. Glassy , Hideaki Hagiwara , Yoshihide Hagiwara
发明人： Harold H. Handley , Mark C. Glassy , Hideaki Hagiwara , Yoshihide Hagiwara
IPC分类号： C07K16/18 , A61K20060101 , A61K39/395 , A61K47/48 , A61K51/10 , A61P35/00 , C07K16/30 , C12N5/00 , C12N5/24 , C12N15/00 , C12P21/00 , C12P21/02 , G01N33/50 , G01N33/53 , G01N33/577
CPC分类号： A61K47/48823 , A61K47/48569 , A61K51/1045 , C07K16/30 , A61K2039/505 , C07K2317/21
摘要： CLNH5 and CLNH11-specific hybridomas, human monoclonal antibodies and their uses are provided. The antibodies distinguish a human neoplastic cell from a normal cell of the same tissue type. The monoclonal antibodies find use in therapy and diagnosis, both in vitro and in vivo.
摘要翻译：提供CLNH5和CLNH11特异性杂交瘤，人单克隆抗体及其用途。抗体将人肿瘤细胞与相同组织类型的正常细胞区分开。单克隆抗体在体外和体内均可用于治疗和诊断。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式